Ochre Bio CEO Jack O'Meara discusses his company's focus on liver diseases and its recent Boehringer Ingelheim partnership
- blonca9
- May 6, 2024
- 1 min read
Jack O'Meara describes Ochre's unique preclinical testing strategy as it develops siRNA drugs for liver diseases, and he touches on a high profile partnership the company signed in recent weeks.